Skip to content
CityAM
Main navigation
Sign Up
  • News
    • Latest News
    • Property
    • Business
    • Media
    • Technology
    • Retail and leisure
    • Transport and infrastructure
    • Law & professional services
    • Legal Notices
    • Banking
    • Politics
    • CFA Institute Talk
    • ICAS Talk
    • Warwick Business School
    • The University of Bath
    • AON
  • Markets & Economics
    • Markets & Economics News
    • Economics
    • Markets
    • Schroders Talk
    • eToro Talk
    • IG Talk
    • M&A Talk
    • BCB Talk
  • Crypto A.M.
    • Crypto News
    • CoinCorner Talk
  • Opinion
    • Features
    • Letters
    • The City View
  • Jobs and Money
    • Jobs and Money News
    • Personal Development
    • Jobs
    • Fintech
    • Money
    • Personal Finance
    • Doceo
    • The Business Guide
    • Finance & Legal
  • Unwind
    • Unwind
    • Sport
    • Six Nations 2022
    • The Punter
    • The Punter Podcast
    • Culture
    • Life & Style
    • Sport Business
    • The Magazine
    • Travel
    • Discover Malta
    • Green Economy
    • The DiverCity Podcast
    • Aramco Team Series
    • Queen’s Award 2022
    • Health, Fitness, and Wellbeing
  • Charity
    • Giving
    • World’s biggest donors 2010 – 2021
  • Latest Paper
  • Jobs

GlaxoSmithKline

  • Glaxosmithkline signs $2bn cancer treatment deal with US biotech firm

    June 15, 2021

    Glaxosmithkline has agreed to pay a US biotech firm as much as $2.1bn (£1.5bn) to team up on an experimental new cancer treatment. The British pharma giant will pay iTeos Therapeutics $625m upfront to co-develop and co-commercialise an immuno-oncology drug known as EOS-448. iTeos will be entitled to receive up to a further $1.5bn if [...]

  • GSK granted US FDA approval for Covid-19 antibody drug

    May 27, 2021

    GSK granted US FDA approval for Covid-19 antibody drug

  • Top shareholders offer support to GSK following activist hedge fund investment

    May 17, 2021

    Several of GlaxoSmithKline’s top shareholders have contacted its chairman to offer support, following concerns activist hedge fund Elliott Management is preparing to push for a shake-up at the group. Shareholders including BlackRock, Dodge & Cox and Royal London are said to have given their support, the Times first reported. The pharma giant has come under [...]

  • GSK profit drops sharply due to pandemic but beats forecasts

    April 28, 2021

    Pharma giant GSK saw its profit and turnover slip in the first quarter due to the impact of the coronavirus pandemic, but came in ahead of analyst expectations. The FTSE 100 firm said that adjusted operating profit fell 30 per cent in the period, down to £1.9bn. Turnover slid 18 per cent to £7.4bn, it [...]

  • GlaxoSmithKline share price leaps at news of activist hedge fund interest

    April 16, 2021

    Shares in GlaxoSmithKline continued to rise on Friday after it emerged that activist hedge fund Elliot Management had built a large stake in the company. New York-based firm Elliot Management, run by billionaire Paul Singer, is believed to have made the multibillion-pound investment earlier this week. GSK was one of the FTSE 100’s biggest risers [...]

  • The week ahead, 1-5 February: FTSE heavyweights front up to third lockdown

    January 31, 2021

    After a turbulent opening to 2021, with new Covid-19 lockdowns around the world, spats over “vaccine nationalism”, and chaos on both Wall Street and Pennsylvania Avenue, a slew of FTSE heavyweights are set to update the market in what will be a crunch week for London’s indices. Despite a strong opening week, the FTSE 100 [...]

  • Asian consumers, boomerang businesses and M&A likely to shape 2021

    January 6, 2021

    It was some year. Anyone who took on the challenge of forecasting what would happen in 2020 more than likely saw it all swiftly swept aside – but, as they say, prediction is very difficult, especially when it’s about the future.  Still, investing is a forward-looking profession and so we inevitably find ourselves thinking about [...]

  • How close are we to having an approved coronavirus vaccine?

    October 28, 2020

    There are a number of vaccine programmes which have advanced to stage three trials, the final hurdle before approval, including two based in the UK. How are they progressing?

  • GSK profit falls a fifth in the third quarter

    October 28, 2020

    Glaxosmithkline (GSK) saw profit attributable to shareholders slip nearly a fifth in the third quarter, but said it was on track to deliver on its guidance for the year. The update came after the pharma giant announced that it would provide a global coronavirus vaccine programme with 200m doses of its candidate. Over the three [...]

  • GSK and Sanofi begin human trials of coronavirus vaccine

    September 3, 2020

    Glaxosmithkline (GSK) has today announced that it is beginning human trials of the coronavirus vaccine it is developing with French pharma firm Sanofi. The two joined forces back in April to develop the potential vaccine, testing of which is now ready to move to the next stage after promising initial results. The combined phase 1 [...]

Posts navigation

  • Previous
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • …
  • Page 13
  • Next

Trending Articles

  • Deloitte, KPMG, PwC and EY push further into India as all Big Four firms go on aggressive hiring spree

  • Brexit beating for British scientists as academics sound alarm over UK exclusion from £95bn Horizon program

  • French citizenship confirmed: Boris Johnson's father Stanley becomes EU national while UK faces Brussels head on over Brexit

  • Nationwide posts strongest results on record on the back of Britain's booming property market

Subscribe

Subscribe to the City A.M. newsletter to have our top stories delivered directly to your inbox.

Subscribe
  • About us
  • Advertising
  • Contact
  • Terms & Conditions
  • Privacy Policy
  • News
  • Markets & Economics
  • Opinion
  • Jobs and Money
  • Unwind
  • Crypto A.M.
  • The Punter
  • COP 26
  • Awards 2019

Follow us for breaking news and latest updates

  • Newsletters
  • Latest paper
  • Advertising
  • CryptoAM.io
  • Awards
  • About
  • Tickets
Copyright 2022 City A.M. Limited